In this episode of BioTalk, Amy C. Hay, Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), joins the conversation to explore the evolving landscape of cell and gene therapy. Amy shares insights from her extensive career in oncology care and innovation, highlighting the role CTMC—a joint venture between National Resilience and MD Anderson Cancer Center—is playing in accelerating the transition from discovery to commercialization. She discusses the current state of the industry, what disruption really means in this context, and how new business models can drive stability and impact for early-stage biotech companies. Amy also offers her perspective on how manufacturing must evolve to meet clinical demand, and how CTMC is positioned to lead in this next era of therapeutic development.
Listen now via your favorite podcast platform:
Apple: https://apple.co/44dfCYa
Spotify: https://spoti.fi/45SJ3Qv
iHeart: https://ihr.fm/4k7Ck9b
YouTube: https://bit.ly/4jYZ23e
Amazon: https://amzn.to/4k7CoFX
TuneIn: https://bit.ly/3HyBF2X
Editing and post-production work for this episode was provided by The Podcast Consultant.
Amy C. Hay is the Chief Business and Strategy Officer at the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience and MD Anderson Cancer Center. She brings decades of experience in oncology care, strategic growth, and healthcare innovation to her role, where she leads business strategy, partnerships, and long-term growth initiatives. Prior to CTMC, Amy held leadership roles at Varian (a Siemens Healthineers company), MD Anderson Cancer Center, and several global consulting efforts focused on advancing cancer care. Her career spans work across the U.S. and internationally, with a focus on driving innovation, commercialization, and patient access in complex health systems.